מכפיל P/S עתידי: Lifeward (LFWD)

ReWalk Robotics Ltd. (LFWD) develops advanced biomechanical exoskeletons to restore patient mobility. However, expansion and acquisition costs currently exceed operating revenues, creating a liquidity deficit. The forward P/S multiple illustrates this imbalance, where the value 0.70 represents the current metric. In the long term, the deployment of systems in clinics will ensure a steady cash flow through ancillary services.

For ReWalk Robotics Ltd. (LFWD), the expected price-to-sales ratio serves as an indicator of market value relative to projected sales, allowing for the identification of asset overvaluation or hidden business degradation. Comparing market capitalization with future revenues helps investors determine a fair bottom, given that the integration of exoskeletons into US and EU clinics offsets local Israeli risks, ensuring the fundamental stability of the model.